NKGen Biotech confirms successful acquisition of NKMax
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 09 2025
0mins
Acquisition Announcement: NKGen Biotech has successfully acquired a majority equity stake in NKMax, a Korean biotechnology company, which was previously in bankruptcy.
Strategic Implications: This acquisition allows NKGen to gain full control over essential global manufacturing infrastructure, intellectual property, and exclusive commercialization rights, enhancing its position in NK cell therapeutics.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
